Product Description
Basiliximab is a chimeric anti-intcrleukin-2 receptor monoclonal antibody. Basiliximab is a glycoprotein produced by recombinant technology. It is used to prevent white blood cells from acute renal transplantation rejection. It specifically binds to and blocks the alpha chain of interleukin-2 receptors (IL-2R alpha), also known as CD25 antigen, on the surface of activated T-lymphocytes. Due to its monoclonal nature it provides safer and more predictable therapeutic, that is, immunosuppressive response of the polyclonal antibodies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15648237/)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, New Zealand
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Gingivitis|Intestinal Diseases
Phase 1: Hepatitis B
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Hepatitis B|Intestinal Diseases |
2017-08-31 |
|||
| 2006-7041-83/hah | P2 |
Not yet recruiting |
Gingivitis|Intestinal Diseases |
2019-12-06 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/04/2023 |
News Article |
Focal Segmental Glomerulosclerosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated) |
|
10/03/2023 |
News Article |
Industrial Gas Spring Market Qualitative Insights on Application & Outlook by Share, Future Growth |
|
09/25/2023 |
News Article |
PET & CT Scan Market 2023 Production, Industry Statistics, Size, Growth, Overview, and Forecast Report till 2030 |
|
09/13/2023 |
News Article |
2023 Basiliximab Injection Market Insights 2031 |